MARATTO

article · International Journal of Risk & Safety in Medicine

Adverse reactions to <i>Rubia peregrina</i> L.: Two case reports from Morocco

Abstract

BackgroundMedicinal plants (MPs) can cause adverse reactions (ARs) particularly affecting major detoxification organs, the kidneys. This study aims to document two cases of nephrotoxicity associated with <i>Rubia peregrina</i> L. (<i>R. peregrina)</i>, a plant recognized for its medicinal properties but also potential toxicity.MethodsAn ethnobotanical study was conducted at Ibn Sina Hospital in Rabat, Morocco, involving two female patients aged 59 and 75, both presenting with anemia and no prior history of renal disease. Data were collected using a semi-structured questionnaire, and plant samples were identified. The study received ethical approval (n°05/23).Case presentationCase 1: A 59-year-old woman developed chronic renal failure requiring hemodialysis after ingesting madder root powder. Causality assessment indicated a possible link to the use of the plant. Case 2: A 75-year-old woman experienced renal failure following the consumption of a madder root decoction. Causality assessment also suggested a possible association.Neither patient had reported ARs prior to hospitalization.ConclusionsThis study is the first to document ARs linked to <i>R. peregrina</i> in humans, highlighting the avant nephrotoxic risks associated with its anthraquinone compounds. Despite its traditional use, the potential for serious renal damage calls for caution, further research, and regulatory measures for MPs.

Research topics

  • Morinda citrifolia extract uses
  • Phytochemistry and biological activity of medicinal plants
  • Hibiscus Plant Research Studies

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1177/09246479261427137

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.